Omics Approaches and Technologies in COVID-19

Table of Contents

1. Omics approaches in COVID-19: An overview2. Genomics, metagenomics, and pan-genomics approaches in COVID-193. Genotype and phenotype correlations in COVID-194. Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives5. Metabolites and metabolomics in COVID-196. Host-pathogen protein-protein interactions and interactomics in COVID-197. Currently available COVID-19 management options8. Transcriptomic approaches in COVID-19: From infection to vaccines9. miRNAomics in COVID-1910. Epigenetic features, methods, and implementations associated with COVID-1911. Nutrigenetics and nutrition aspects in COVID-1912. COVID-19 phenomics13. Applications of genetic engineering in COVID-1914. CRISPR-based assays for rapid detection of SARS-CoV-215. Emergence and dynamics of COVID-19 and future pandemics16. Artificial intelligence in COVID-1917. Applications of mathematical modeling and simulation in COVID-1918. In silico disease modeling for COVID-1919. Systems biology in COVID-1920. Computational approaches for drug discovery against COVID-1921. Computational approaches in COVID-19 vaccine development22. Applications of multiomics data in COVID-1923. Publicly available resources in COVID-19 research and their applications24. Emerging technologies for COVID-19, diagnosis, prevention, and management25. Applications of digital and smart technologies to control SARS-CoV-2 transmission, rapid diagnosis, and monitoring26. Application of big data analytics in the COVID-19 pandemic: Selected problems

Authors

Debmalya Barh Federal University of Minas Gerais, Belo Horizonte, Brazil. Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) in Bioinformatics and Precision Health at the Department of Genetics, Ecology, and Evolution, ICB, Federal University of Minas Gerais, Brazil and honorary scientist of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. With over 20 years of experience, he has led academic, healthcare, molecular diagnostic, and bioinformatics industry endeavors. He works with more than 400 scientists from 100+ top ranked organizations across 40+ countries and has 220+ publications and a branded editor for 10+ cutting-edge omics related reference books. He is an expert in in precision/personalized health and integrative omics-based biomarker and target discovery in infectious and complex lifestyle diseases. Vasco Ariston De Car Azevedo Professor, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Brazil. Dr. Vasco Azevedo is a full professor at the Department of Genetics, Ecology, and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. He is a CNPq (Conselho Nacional de Desenvolvimento Cient�fico e Tecnol�gico) researcher 1A, member of the Brazilian Academy of Sciences, Commander of the Order of Scientific Merit of the MCTI of the genetics advisory committee and the public policy working group on biotechnology and genetic resources of COBRG/CNPq, coordinator of the Associated International Laboratory Bactinfl from INRAE and UFMG, and vice-president of the Brazilian Association of Bioinformatics and Computational Biology. He holds a degree in veterinary medicine from the School of Veterinary Medicine of the Federal University of Bahia (1986), a master's degree (1989), a doctorate (1993) in the genetics of microorganisms from the Institut National Agronomique Paris Grignon, and a doctorate in bioinformatics from UFMG (2017). He did his postdoctorate work with the Department of Microbiology, School of Medicine, University of Pennsylvania, United States (1994). He was a professor at the Institute of Biomedical Sciences of the University of S�o Paulo (2004). He is an expert in genetics and bioinformatics and his work mainly focuses on genomics, transcriptomics, proteomics, metabolomics, vaccine development, diagnostics, and the development of next generation probiotics. He has more than 600 scientific publications, 14 books, and 60 chapters as well as 12 patents.